Methylene Chloride

Methylene Chloride

SCHEMBL1832445

CO.CO.CO.CO.CO.CO.CO.CO.CO.CO.CO.CO.CO.CO.CO.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl.ClCCl

nearest known ligand 0.57

Full drug profile on Sugi Atlas →

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.57
TSHR P16473 5/20 0.43
HSD17B10 Q99714 1/20 0.39
TDP1 Q9NUW8 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Methylene Chloride SCHEMBL465908 1.00 ALDH1A1 (0.57) ALDH1A1TSHRHSD17B10TDP1
Methylene Chloride SCHEMBL9625167 1.00 ALDH1A1 (0.57) ALDH1A1TSHRHSD17B10TDP1
Methylene Chloride SCHEMBL4933917 1.00 ALDH1A1 (0.57) ALDH1A1TSHRHSD17B10TDP1
Methylene Chloride SCHEMBL992285 1.00 ALDH1A1 (0.57) ALDH1A1TSHRHSD17B10TDP1
Methylene Chloride SCHEMBL292514 1.00 ALDH1A1 (0.57) ALDH1A1TSHRHSD17B10TDP1
Methylene Chloride SCHEMBL3199266 1.00 ALDH1A1 (0.57) ALDH1A1TSHRHSD17B10TDP1
Methylene Chloride SCHEMBL7090995 1.00 ALDH1A1 (0.57) ALDH1A1TSHRHSD17B10TDP1
Methylene Chloride SCHEMBL4784041 1.00 ALDH1A1 (0.57) ALDH1A1TSHRHSD17B10TDP1
Methylene Chloride SCHEMBL2031974 1.00 ALDH1A1 (0.57) ALDH1A1TSHRHSD17B10TDP1
Methylene Chloride SCHEMBL948 1.00

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11845874-B2 Radiation curable inkjet inks for interior decoration AGFA NV (BE) 2023-12-19 US disclosed
US-20220119662-A1 RADIATION CURABLE INKJET INKS FOR INTERIOR DECORATION AGFA NV (BE) 2022-04-21 US disclosed
EP-3914655-A1 RADIATION CURABLE INKJET INKS FOR INTERIOR DECORATION AGFA NV (BE) 2021-12-01 EP disclosed
WO-2020152037-A1 RADIATION CURABLE INKJET INKS FOR INTERIOR DECORATION AGFA NV (BE) 2020-07-30 WO disclosed
CN-102918042-B 8-methyl-1-phenyl-imidazo [1,5-a ] pyrazine compounds MERCK SHARP & DOHME B.V. (NL) 2016-03-09 CN disclosed
CN-101742909-B Use of compounds having a monogalactosyldiacylglycerol synthase inhibitory activity as herbicide or algaecide, herbicide and algaecide compositions COMMISSARIAT ENERGIE ATOMIQUE 2014-07-09 CN disclosed
CN-102918042-A 8-methyl-1-phenyl-imidazo [1,5-a ] pyrazine compounds MSD OSS BV 2013-02-06 CN disclosed
EP-2361920-A2 Preparation and use of carbohydrate-based ring structures with antimicrobial and cytostatic activity Kemin Pharma Europe (US) 2011-08-31 EP disclosed
EP-2160098-B9 USE OF COMPOUNDS HAVING A MONOGALACTOSYLDIACYLGLYCEROL SYNTHASE INHIBITORY ACTIVITY AS HERBICIDE OR ALGAECIDE, HERBICIDE AND ALGAECIDE COMPOSITIONS COMMISSARIAT ENERGIE ATOMIQUE (FR) 2011-05-18 EP disclosed
US-20100292214-A1 Compounds with Antiparasitic Activity, Applications thereof to the Treatment of Infectious Diseases Caused by Apicomplexans COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) 2010-11-18 US disclosed
US-5567694-A ANDROSTANE ENE STEROIDS; HYPOTENSIVE AGENT FOR LOWER BLOOD PRESSURE SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) 1996-10-22 US disclosed
US-5538963-A BACTERICIDE ANTIBIOTICS ROUSSEL UCLAF (FR) 1996-07-23 US disclosed
US-5378697-A BACTERICIDES ROUSSEL-UCLAF (FR) 1995-01-03 US disclosed
EP-0590272-A2 17B-Aryl and 17B-heterocyclyl-5-beta,14-beta-andostane derivatives active on the cardiovascular system, processes for their preparation and pharmaceutical compositions containing same Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) 1994-04-06 EP disclosed
EP-0583578-A2 17-(3-Furyl) and 17-(4-pyridazinyl)-5beta,14beta-androstane derivatives active on the cardiovascular system, processes for their preparation and pharmaceutical compositions containing same Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) 1994-02-23 EP disclosed
EP-0167204-B1 METHOD FOR IMPROVING THE ABSORPTION AND EFFECTIVENESS OF A CATECHOLAMINE COMPOUND SIMES S.p.A. Società Italiana Medicinali e Sintetici (IT) 1989-09-27 EP disclosed
US-4673671-A CONVERSION TO MONO O-PHOSPHATE ESTER SIMES SOCIETA ITALIANA MEDICINALI E SINTETICI S.P.A. (IT) 1987-06-16 US disclosed
US-4593022-A Antibiotics SANOFI (FR) 1986-06-03 US disclosed
EP-0167204-A1 Method for improving the absorption and effectiveness of a catecholamine compound SIMES S.p.A. Società Italiana Medicinali e Sintetici (IT) 1986-01-08 EP disclosed
US-4385181-A CHAMICAL INTERMEDIATES FOR CEPHALOSPORINS RHONE POULENC INDUSTRIES (FR) 1983-05-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100292214-A1 Compounds with Antiparasitic Activity, Applications thereof to the Treatment of Infectious Diseases Caused by Apicomplexans ABCB11, TPP1, ABCB1 ALDH1A1 898/4885TSHR 4703/4885HSD17B10 1030/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.